SCHEMBL5237313

SCHEMBL5237313

O=C(Cc1ccnc2ccccc12)c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.56
CYP1A2 P05177 1/20 0.52
LOXL2 Q9Y4K0 1/20 0.46
ALDH1A1 P00352 5/20 0.46
NPC1 O15118 4/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 2/20 0.45
GLA P06280 1/20 0.45
MAPT P10636 5/20 0.45
LMNA P02545 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 1/20 0.45
NPSR1 Q6W5P4 3/20 0.44
TP53 P04637 1/20 0.43
CTSD P07339 1/20 0.43
GUSB P08236 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29987166 0.88 CYP1A2 (0.61) RAB9ACYP1A2LOXL2ALDH1A1NPC1
SCHEMBL5239658 0.88 CYP1A2 (0.61) RAB9ACYP1A2LOXL2ALDH1A1NPC1
SCHEMBL5233678 0.85 RAB9A (0.56) RAB9ACYP1A2LOXL2ALDH1A1NPC1
SCHEMBL5239397 0.85 CNR2 (0.50) CYP1A2LOXL2KDM4EGLAKMT2A
SCHEMBL5231753 0.85 CYP1A2 (0.53) RAB9ACYP1A2LOXL2NPC1HPGD
SCHEMBL5240712 0.82 CYP1A2 (0.49) RAB9ACYP1A2LOXL2PTPN1NCF1
SCHEMBL5236277 0.79 CYP1A2 (0.52) RAB9ACYP1A2LOXL2ALDH1A1NPC1
SCHEMBL5239743 0.79 VNN1 (0.44) CYP1A2LOXL2
SCHEMBL5235487 0.79 CYP1A2 (0.44) CYP1A2LOXL2CYP3A4
SCHEMBL5234952 0.79 LOXL2 (0.46) RAB9ACYP1A2LOXL2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1397364-B1 NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS LILLY CO ELI (US) 2007-07-25 EP disclosed
US-6645989-B2 Antiinflammatory agents SMITHKLINE BEECHAM CORPORATION 2003-11-11 US disclosed
US-20030064997-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2003-04-03 US disclosed
US-6268370-B1 CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION 2001-07-31 US disclosed
US-5916891-A CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1999-06-29 US disclosed
US-5686455-A Imidazole derivatives and their use as cytokine inhibitors SMITHKLINE BEECHAM CORPORATION (US) 1997-11-11 US disclosed
US-5656644-A CYTOKINE SUPPRESSORS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-12 US disclosed
EP-0623126-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1994-11-09 EP disclosed
WO-1993014081-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1993-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064997-A1 Novel compounds BRD4, BRDT, HDAC6 RAB9A 929/4885CYP1A2 517/4885LOXL2 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.